CN1062269C - 新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃 - Google Patents

新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃 Download PDF

Info

Publication number
CN1062269C
CN1062269C CN94194312A CN94194312A CN1062269C CN 1062269 C CN1062269 C CN 1062269C CN 94194312 A CN94194312 A CN 94194312A CN 94194312 A CN94194312 A CN 94194312A CN 1062269 C CN1062269 C CN 1062269C
Authority
CN
China
Prior art keywords
dihydro
fluoro
chromene
compound
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94194312A
Other languages
English (en)
Chinese (zh)
Other versions
CN1136811A (zh
Inventor
J·L·埃文邓
E·M·哈马伯格
H·S·汉森
S·E·海尔伯格
L·G·约翰松
J·R·M·隆德-克维斯特
S·B·罗斯
D·D·佐恩
S·O·图尔伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of CN1136811A publication Critical patent/CN1136811A/zh
Application granted granted Critical
Publication of CN1062269C publication Critical patent/CN1062269C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN94194312A 1993-10-28 1994-10-26 新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃 Expired - Fee Related CN1062269C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,671 US5420151A (en) 1989-12-22 1993-10-28 Chroman derivatives
US144671 1993-10-28

Publications (2)

Publication Number Publication Date
CN1136811A CN1136811A (zh) 1996-11-27
CN1062269C true CN1062269C (zh) 2001-02-21

Family

ID=22509617

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194312A Expired - Fee Related CN1062269C (zh) 1993-10-28 1994-10-26 新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃

Country Status (35)

Country Link
US (9) US5420151A (enExample)
EP (1) EP0725779B1 (enExample)
JP (1) JP3089276B2 (enExample)
CN (1) CN1062269C (enExample)
AT (1) ATE203019T1 (enExample)
AU (1) AU687115B2 (enExample)
BR (1) BR9407910A (enExample)
CA (1) CA2173257C (enExample)
CZ (1) CZ284371B6 (enExample)
DE (1) DE69427704T2 (enExample)
DK (1) DK0725779T3 (enExample)
EE (1) EE03253B1 (enExample)
ES (1) ES2160640T3 (enExample)
FI (1) FI961809L (enExample)
GR (1) GR3036816T3 (enExample)
HR (1) HRP940890B1 (enExample)
HU (1) HUT75060A (enExample)
IL (1) IL111365A (enExample)
IS (1) IS1904B (enExample)
LV (1) LV12811B (enExample)
MY (1) MY111616A (enExample)
NO (1) NO314146B1 (enExample)
NZ (1) NZ275176A (enExample)
PL (1) PL178840B1 (enExample)
PT (1) PT725779E (enExample)
RU (1) RU2142951C1 (enExample)
SA (1) SA94150317B1 (enExample)
SG (1) SG52320A1 (enExample)
SI (1) SI0725779T1 (enExample)
SK (1) SK280527B6 (enExample)
TW (1) TW399049B (enExample)
UA (1) UA44717C2 (enExample)
WO (1) WO1995011891A1 (enExample)
YU (1) YU49048B (enExample)
ZA (1) ZA948353B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
CA2153498A1 (en) * 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
SE9701438D0 (sv) * 1997-04-17 1997-04-17 Astra Ab A new process
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
NZ535574A (en) 2001-01-16 2006-07-28 Astrazeneca Ab Therapeutic heterocyclic compounds
US7032572B2 (en) * 2002-06-04 2006-04-25 Ford Global Technologies, Llc Method for controlling an engine to obtain rapid catalyst heating
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
KR20070088798A (ko) * 2004-12-21 2007-08-29 에프. 호프만-라 로슈 아게 크로만 유도체 및 그의 5-ｈｔ 수용체 리간드로서의 용도
US20060205807A1 (en) * 2005-02-16 2006-09-14 Wyeth Amino-chroman compounds and methods for preparing same
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
BRPI0718351A2 (pt) * 2006-12-12 2019-09-24 Bial Portela & Ca Sa "processo para a preparação do enantiômero s ou r, processo para formar um composto r ou s, uso de um catalisador quiral, composto, sal tartrato do enantiômero s ou r de um composto, complexo de metal de transição e catalisador"
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) * 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
CA2972203C (en) 2017-06-29 2018-07-17 Exxonmobil Upstream Research Company Chasing solvent for enhanced recovery processes
CA2974712C (en) 2017-07-27 2018-09-25 Imperial Oil Resources Limited Enhanced methods for recovering viscous hydrocarbons from a subterranean formation as a follow-up to thermal recovery processes
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
CA2978157C (en) 2017-08-31 2018-10-16 Exxonmobil Upstream Research Company Thermal recovery methods for recovering viscous hydrocarbons from a subterranean formation
CA2983541C (en) 2017-10-24 2019-01-22 Exxonmobil Upstream Research Company Systems and methods for dynamic liquid level monitoring and control
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12007369B2 (en) * 2021-04-01 2024-06-11 Saudi Arabian Oil Company Residual corrosion inhibitor monitoring

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009853A1 (en) * 1989-12-22 1991-07-11 Aktiebolaget Astra New chroman and thiochroman derivatives
WO1993007135A1 (en) * 1991-10-08 1993-04-15 Aktiebolaget Astra 3-(n-isopropyl-n-n-propylamino)-5-(n-isopropyl)carbamoylchroman

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795874A (fr) * 1972-02-25 1973-08-23 Glaxo Lab Ltd Procede de preparation d'esters optiquement actifs d'alpha-amino-acides
JPS60152425A (ja) * 1984-01-20 1985-08-10 Oyo Seikagaku Kenkyusho:Kk ラセミ体の新規な光学分割法
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
PH22522A (en) * 1985-09-03 1988-10-17 Ciba Geigy Ag 3-amino-dihydro-1-benzopyrans and benzothiopyrans, their pharmaceutical compositions and method of using said compounds
FR2593504B1 (fr) * 1986-01-30 1988-12-09 Ile De France Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
US5026707A (en) * 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
IL93464A (en) * 1989-02-27 1996-10-16 Lilly Co Eli 2-Amino-1,2,3,4-Tetrahydronaplanin and 3 aminochromes with a transformed ring, a process for their preparation and pharmaceutical preparations containing them
US5306830A (en) * 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
DE3942418A1 (de) * 1989-12-21 1991-06-27 Guenther Strecker Gestellstab
EP0471515B1 (en) * 1990-08-15 1997-03-05 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009853A1 (en) * 1989-12-22 1991-07-11 Aktiebolaget Astra New chroman and thiochroman derivatives
WO1993007135A1 (en) * 1991-10-08 1993-04-15 Aktiebolaget Astra 3-(n-isopropyl-n-n-propylamino)-5-(n-isopropyl)carbamoylchroman

Also Published As

Publication number Publication date
EP0725779B1 (en) 2001-07-11
US5646309A (en) 1997-07-08
IL111365A (en) 2000-12-06
EP0725779A1 (en) 1996-08-14
PT725779E (pt) 2001-12-28
WO1995011891A1 (en) 1995-05-04
YU62294A (sh) 1997-07-31
RU2142951C1 (ru) 1999-12-20
US5639772A (en) 1997-06-17
GR3036816T3 (en) 2002-01-31
JPH09504287A (ja) 1997-04-28
SG52320A1 (en) 1998-09-28
US5420151A (en) 1995-05-30
PL178840B1 (pl) 2000-06-30
FI961809A7 (fi) 1996-05-20
DE69427704D1 (de) 2001-08-16
CN1136811A (zh) 1996-11-27
FI961809L (fi) 1996-05-20
NO961687D0 (no) 1996-04-26
UA44717C2 (uk) 2002-03-15
IL111365A0 (en) 1994-12-29
PL314086A1 (en) 1996-08-19
CA2173257C (en) 2005-12-06
US5641807A (en) 1997-06-24
FI961809A0 (fi) 1996-04-26
NO314146B1 (no) 2003-02-03
AU8069794A (en) 1995-05-22
SI0725779T1 (enExample) 2001-12-31
IS4226A (is) 1995-04-29
CZ111496A3 (en) 1996-09-11
US5650524A (en) 1997-07-22
HRP940890A2 (en) 1996-12-31
DK0725779T3 (da) 2001-10-29
NZ275176A (en) 1997-11-24
SK43696A3 (en) 1996-10-02
HUT75060A (en) 1997-03-28
ES2160640T3 (es) 2001-11-16
HRP940890B1 (en) 2001-12-31
CZ284371B6 (cs) 1998-11-11
US5656657A (en) 1997-08-12
IS1904B (is) 2003-11-20
AU687115B2 (en) 1998-02-19
LV12811B (lv) 2002-08-20
ZA948353B (en) 1995-05-02
HU9601103D0 (en) 1996-06-28
DE69427704T2 (de) 2002-05-02
HK1002898A1 (en) 1998-09-25
YU49048B (sh) 2003-07-07
US5500425A (en) 1996-03-19
TW399049B (en) 2000-07-21
EE03253B1 (et) 2000-02-15
SA94150317B1 (ar) 2005-10-15
US5639784A (en) 1997-06-17
NO961687L (no) 1996-06-03
LV12811A (en) 2002-04-20
US5656658A (en) 1997-08-12
CA2173257A1 (en) 1995-05-04
JP3089276B2 (ja) 2000-09-18
SK280527B6 (sk) 2000-03-13
BR9407910A (pt) 1996-11-26
ATE203019T1 (de) 2001-07-15
MY111616A (en) 2000-09-27

Similar Documents

Publication Publication Date Title
CN1136811A (zh) 新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃
CN1073101C (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1077574C (zh) 托烷衍生物,其制备和应用
CN1092643C (zh) 用于增强记忆的氨甲基苯基咪唑衍生物
CN1064356C (zh) 新哌嗪、哌啶与1,2,5,6－四氢吡啶化合物，其制法及其药物组合物
CN1438220A (zh) 1－（1，2－双取代哌啶基〕－4－取代哌嗪衍生物
CN101039908A (zh) 作为11－β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
CN1294577A (zh) 钾通道抑制剂
CN1035508A (zh) 新的取代的喹啉衍生物的制备方法
CN1124960A (zh) 作为5-ht/a和/或5-ht2配体的吲哚衍生物
CN1209805A (zh) 新型稠合的吡咯碳酰胺、新一类的gaba脑受体配位体
CN1671662A (zh) 哌啶衍生物及其制备方法和用途
CN1040979C (zh) 抑制精神活动的方法
CN1111986A (zh) 治疗肠应激综合症的异噁唑衍生物
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1032440A (zh) 4-氨基吡啶衍生物类
CN1889940A (zh) 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
CN1107066C (zh) 二氮杂－螺[3,5]壬烷衍生物
CN1031262C (zh) 环取代的2-氨基-1，2，3，4-四氢化萘和3-氨基苯并二氢吡喃
CN1105360A (zh) 1-[2h-1-苯并吡喃-2-酮-8-基]-哌嗪衍生物
CN1190967A (zh) 杂环甲酰胺衍生物及其作为治疗剂的用途
CN101044145A (zh) 咪唑并－苯并二氮杂䓬衍生物
CN1245169A (zh) 新的硝酮化合物,其制备方法以及含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1024606

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee